Skip to main content
TipRanks
Go Ultimate75% OFF

HYUGA PRIMARY CARE Co.,Ltd. (7133) AI Stock Analysis

0 Followers
JP:7133

HYUGA PRIMARY CARE Co.,Ltd.

(TSE/TYO:7133)

Select Model
Rating:63Neutral
Price Target:JPY 1,748.00â–¼(-16.12% Downside)
Action:reiterated
Date:09/29/26

The score is held back primarily by weakening financial quality in 2026—margin compression, reduced earnings, higher leverage, and a sharp drop in cash conversion/free cash flow. These risks are partially offset by strong technical momentum (clear uptrend with positive MACD) and a broadly reasonable valuation (moderate P/E with a modest dividend yield).

Positive Factors
Consistent Revenue GrowthSustained revenue expansion indicates continued demand for the company’s pharmacy and primary-care support services. Growth at this pace can broaden the operating base, improve scale economics, and provide resources to reinvest in patient support and service capacity over the next several quarters.
Negative Factors
Margin CompressionThe sharp decline in gross and net margins shows that higher sales are not currently translating into proportional profit growth. If cost pressure or unfavorable mix persists, earnings quality could remain weaker and reduce the funds available for expansion, service investment, or balance-sheet improvement.

HYUGA PRIMARY CARE Co.,Ltd. (7133) vs. iShares MSCI Japan ETF (EWJ)

-25%0%25%50%75%100%125%JP:7133+101.09%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 14.86B
Dividend Yield
0.96%
Average Volume (3M)
32.44K
Price to Earnings (P/E)
24.2
Beta (1Y)
0.09
Revenue Growth
20.66%
EPS Growth
-12.73%
Country
Japan
Employees
882
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model

Company Description

HYUGA PRIMARY CARE Co.,Ltd., established in 2007 and based in Kasuga, Japan, specializes in delivering a variety of primary care services, encompassing home-visit pharmacies, nursing support, and personalized care planning. The company extends its ex...

How the Company Makes Money

The company primarily generates revenue through dispensing-pharmacy operations, where it earns fees associated with filling prescriptions issued by medical institutions and receives payment for providing medication guidance and related pharmacy servi...

HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview

Summary

Strong and consistent revenue growth is a clear positive, but 2026 showed meaningful deterioration in quality: gross and net margins compressed, net income declined despite higher sales, leverage is elevated (higher debt reliance), and cash conversion weakened sharply with free cash flow nearly breakeven.

Income Statement

68Positive

Balance Sheet

56Neutral

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.68B11.98B9.98B8.29B6.66B5.78B
Gross Profit2.38B2.25B2.41B1.88B1.56B1.24B
EBITDA1.37B1.18B1.31B854.38M627.27M568.69M
Net Income614.95M501.88M719.03M441.03M382.88M328.45M
Balance Sheet
Total Assets8.67B8.29B7.05B6.35B2.92B2.54B
Cash, Cash Equivalents and Short-Term Investments1.24B1.02B565.93M688.01M567.69M719.56M
Total Debt2.86B3.22B2.65B2.80B251.54M330.21M
Total Liabilities5.90B5.56B4.68B4.71B1.44B1.46B
Stockholders Equity2.77B2.73B2.37B1.64B1.48B1.07B
Cash Flow
Free Cash Flow035.71M485.51M473.20M102.59M228.92M
Operating Cash Flow0492.94M771.32M706.64M342.25M484.60M
Investing Cash Flow0-319.13M-473.98M-1.13B-383.39M-320.25M
Financing Cash Flow0281.88M-419.43M538.78M-110.73M16.93M

HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price2084.00

Price Trends

50DMA1824.74Positive
100DMA1511.16Positive
200DMA1290.08Positive

Market Momentum

MACD57.44Positive
RSI77.45Negative
STOCH5.04Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Positive. The current price of 2084.00 is below the 20-day moving average (MA) of 2100.35, above the 50-day MA of 1824.74, and above the 200-day MA of 1290.08, indicating a neutral trend. The MACD of 57.44 indicates Positive momentum. The RSI at 77.45 is Negative, neither overbought nor oversold. The STOCH value of 5.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7133.

HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:7133 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7071JP:707164NeutralJPY 35.59B11.37―1.09%6.17%-33.01%
JP:7133JP:713363NeutralJPY 15.15B24.16―0.96%20.66%-12.73%
JP:2425JP:242556NeutralJPY 2.51B28.28―3.36%-3.64%-66.52%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:2373JP:237352NeutralJPY 5.18B18.12―4.42%4.76%-52.55%
JP:7061JP:706141NeutralJPY 3.68B10.96――6.75%-119.69%

* General Sector Average

Performance Comparison

-50%0%50%100%JP:7133JP:2373JP:2425JP:7061JP:7071Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7133 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7133HYUGA PRIMARY CARE Co.,Ltd.2084.001037.8599.21%
JP:2373Care Twentyone Corporation385.00-51.90-11.88%
JP:2425Care Service Co., Ltd.655.00-112.94-14.71%
JP:7061Japan Hospice Holdings Inc.428.00-894.00-67.62%
JP:7071Amvis Holdings.Inc.366.00-88.36-19.45%

HYUGA PRIMARY CARE Co.,Ltd. Corporate Events

HYUGA PRIMARY CARE Unveils Q1 FY2027 Results and Outlook

Aug 27, 2026

HYUGA PRIMARY CARE Co., Ltd. released its financial results for the first quarter of the fiscal year ending March 2027, outlining performance and trends under its TSE Growth Market listing. The disclosure highlights how the quarter’s results fit into...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026